Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Sep 1;5(10):1664-1667.
doi: 10.1002/ccr3.1136. eCollection 2017 Oct.

A rare case of CD1a-negative Langerhans cell histiocytosis of the central nervous system in a child

Affiliations
Case Reports

A rare case of CD1a-negative Langerhans cell histiocytosis of the central nervous system in a child

Priscilla Powell et al. Clin Case Rep. .

Abstract

Langerhans cell histiocytosis is a dendritic cell disorder with a wide spectrum of severity and presentations. Histopathology typically demonstrates a proliferation of Langerhans cells and a lymphohistiocytic inflammatory infiltrate with eosinophils. The diagnosis is supported by immunohistochemistry with the cell markers S100, CD1a, CD68, and Langerin [Blood, 126, 2015, 26 and N Engl J Med, 331, 1994, 154].

Keywords: Basal ganglia; CD1a; Langerhans cell histiocytosis; S100; dendritic cell disorder; diabetes insipidus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
S100 immunohistochemistry. Close examination reveals that the perivascular Langerin‐positive cells express S100 protein. Note that the background glioneuronal tissue is also S100 protein positive.
Figure 2
Figure 2
Histopathology of brain lesion. (A, B) Dendritic cell infiltration with mixed inflammation including histiocytes, lymphocytes, plasma cells, and rare eosinophils (H&E 200× and 400×). (C) Langerhans cells lack CD1a expression (200×). (D) Langerin immunohistochemistry demonstrates Langerhans cells predominantly involving the Virchow–Robin spaces (200×).

References

    1. Lau, S. K. , Chu P. G., and Weiss L. M.. 2008. Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non‐Langerhans cell histiocytic disorders. Am. J. Surg. Pathol. 32:615–619. - PubMed
    1. Broadbent, V. , Egeler R. M., and Nesbit M. E. Jr. 1994. Langerhans cell histiocytosis – clinical and epidemiological aspects. Br. J. Cancer 70:S11–S16. - PMC - PubMed
    1. Willman, C. L. , Busque L., Griffith B. B., Favara B. E., Mcclain K. L., Duncan M. H., et al. 1994. Langerhans’‐cell histiocytosis (Histiocytosis X) – a clonal proliferative disease. N. Engl. J. Med. 331:154–160. - PubMed
    1. Allen, C. E. , Ladisch S., and Mcclain K. L.. 2015. How I treat Langerhans cell histiocytosis. Blood 126:26–35. - PMC - PubMed
    1. Berres, M. , Merad M., and Allen C.E.. 2014. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br. J. Haematol. 169:3–13. - PMC - PubMed

Publication types

LinkOut - more resources